-
公开(公告)号:US20230219905A1
公开(公告)日:2023-07-13
申请号:US18075646
申请日:2022-12-06
IPC分类号: C07D263/52 , C07D235/02 , C07D209/96
CPC分类号: C07D263/52 , C07D235/02 , C07D209/96
摘要: Aldoketo reductase (AKR) inhibitors having formulas I-III are used to treat disorders associated with NO/SNO deficiency.
-
公开(公告)号:US20210347744A1
公开(公告)日:2021-11-11
申请号:US17278559
申请日:2019-09-23
IPC分类号: C07D263/52 , C07D209/96 , C07D235/02
摘要: Aldoketo reductase (AKR) inhibitors having formulas I-III are used to treat disorders associated with NO/SNO deficiency.
-
公开(公告)号:US12098135B2
公开(公告)日:2024-09-24
申请号:US18075646
申请日:2022-12-06
IPC分类号: C07D263/52 , C07D209/96 , C07D235/02
CPC分类号: C07D263/52 , C07D209/96 , C07D235/02
摘要: Aldoketo reductase (AKR) inhibitors having formulas I-III are used to treat disorders associated with NO/SNO deficiency.
-
公开(公告)号:US20230285402A1
公开(公告)日:2023-09-14
申请号:US18117257
申请日:2023-03-03
发明人: Sanford Markowitz , James K. V. Willson , Bruce Posner , Joseph Ready , Monika Antczak , Yongyou Zhang , Amar Desai , Stanton Gerson , William Greenlee , Sung Yeun Yang , KiBeom Bae
IPC分类号: A61K31/5377 , A61K31/4365 , C07D495/04 , A61K31/444 , A61K31/437 , A61K31/496 , A61K31/519
CPC分类号: A61K31/5377 , A61K31/4365 , C07D495/04 , A61K31/444 , A61K31/437 , A61K31/496 , A61K31/519
摘要: Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors described herein.
-
公开(公告)号:US20210094968A1
公开(公告)日:2021-04-01
申请号:US16869879
申请日:2020-05-08
发明人: Sanford Markowitz , Joseph Ready , Yongyou Zhang , Monika Antczak , James K.V. Willson , Bruce Posner , William Greenlee
IPC分类号: C07D495/04 , A61K31/4365 , A61K31/395 , A61K31/519 , A61K31/5377 , A61P7/06 , A61P15/10 , A61P1/02 , A61P9/10 , A61P19/00 , A61P37/04 , A61P39/00 , A61P1/16 , A61P9/00 , A61P17/14 , A61P25/02 , A61P37/06 , A61P17/00 , A61P35/02 , A61P9/12 , A61P13/12 , A61P17/02 , A61P1/00 , A61P9/04 , A61P11/00 , A61P25/00 , A61P25/16 , A61P29/00 , A61P35/04 , A61P1/04 , A61P35/00 , A61K8/49 , A61K9/00 , A61K31/444 , A61K31/4545 , A61K35/28 , A61K38/19 , A61Q7/00 , A61Q19/04
摘要: Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors described herein.
-
公开(公告)号:US20240174688A1
公开(公告)日:2024-05-30
申请号:US18481787
申请日:2023-10-05
发明人: Sanford Markowitz , Joseph Ready , Yongyou Zhang , Monika Antczak , James K.V. Willson , Bruce Posner , William Greenlee
IPC分类号: C07D495/04 , A61K8/49 , A61K9/00 , A61K31/395 , A61K31/4365 , A61K31/444 , A61K31/4545 , A61K31/519 , A61K31/5377 , A61K35/28 , A61K38/19 , A61P1/00 , A61P1/02 , A61P1/04 , A61P1/16 , A61P7/06 , A61P9/00 , A61P9/04 , A61P9/10 , A61P9/12 , A61P11/00 , A61P13/12 , A61P15/10 , A61P17/00 , A61P17/02 , A61P17/14 , A61P19/00 , A61P25/00 , A61P25/02 , A61P25/16 , A61P29/00 , A61P35/00 , A61P35/02 , A61P35/04 , A61P37/04 , A61P37/06 , A61P39/00 , A61Q7/00 , A61Q19/04
CPC分类号: C07D495/04 , A61K8/49 , A61K9/0014 , A61K9/0019 , A61K31/395 , A61K31/4365 , A61K31/444 , A61K31/4545 , A61K31/519 , A61K31/5377 , A61K35/28 , A61K38/193 , A61P1/00 , A61P1/02 , A61P1/04 , A61P1/16 , A61P7/06 , A61P9/00 , A61P9/04 , A61P9/10 , A61P9/12 , A61P11/00 , A61P13/12 , A61P15/10 , A61P17/00 , A61P17/02 , A61P17/14 , A61P19/00 , A61P25/00 , A61P25/02 , A61P25/16 , A61P29/00 , A61P35/00 , A61P35/02 , A61P35/04 , A61P37/04 , A61P37/06 , A61P39/00 , A61Q7/00 , A61Q19/04 , Y02A50/30
摘要: Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors described herein.
-
公开(公告)号:US11518748B2
公开(公告)日:2022-12-06
申请号:US17278559
申请日:2019-09-23
IPC分类号: C07D263/52 , C07D209/96 , C07D235/02
摘要: Aldoketo reductase (AKR) inhibitors having formulas I-III are used to treat disorders associated with NO/SNO deficiency.
-
公开(公告)号:US09789116B2
公开(公告)日:2017-10-17
申请号:US15029943
申请日:2014-10-15
发明人: Sanford Markowitz , James K. V. Willson , Bruce Posner , Joseph Ready , Monika Antczak , Yongyou Zhang , Amar Desai , Stanton Gerson , William Greenlee
IPC分类号: A61K31/535 , A61K31/5377 , A61K31/4365 , A61K31/519 , A61K31/437 , A61K31/444 , A61K31/496
CPC分类号: A61K31/5377 , A61K31/4365 , A61K31/437 , A61K31/444 , A61K31/496 , A61K31/519 , C07D495/04
摘要: Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors described herein.
-
公开(公告)号:US20170173028A1
公开(公告)日:2017-06-22
申请号:US15029943
申请日:2014-10-15
发明人: Sanford Markowitz , James K.V. Willson , Bruce Posner , Joseph Ready , Monika Antczak , Youngyou Zhang , Amar Desai , Stanton Gerson , William Greenlee
IPC分类号: A61K31/5377 , A61K31/496 , A61K31/437 , A61K31/444 , A61K31/4365 , A61K31/519
CPC分类号: A61K31/5377 , A61K31/4365 , A61K31/437 , A61K31/444 , A61K31/496 , A61K31/519 , C07D495/04
摘要: Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors described herein.
-
公开(公告)号:US20210106587A1
公开(公告)日:2021-04-15
申请号:US16997273
申请日:2020-08-19
发明人: Sanford Markowitz , James K.V. Willson , Bruce Posner , Joseph Ready , Monika Antczak , Yongyou Zhang , Amar Desai , Stanton Gerson , William Greenlee , Sung Yeun Yang , KiBeom Bae
IPC分类号: A61K31/5377 , C07D495/04 , A61K31/4365 , A61K31/437 , A61K31/444 , A61K31/496 , A61K31/519
摘要: Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors described herein.
-
-
-
-
-
-
-
-
-